Bausch + Lomb Corporation (TSX:BLCO)
| Market Cap | 9.97B +32.9% |
| Revenue (ttm) | 7.69B +8.9% |
| Net Income | -157.58M |
| EPS | -0.45 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 16.20 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6,732 |
| Open | 28.87 |
| Previous Close | 28.75 |
| Day's Range | 27.74 - 28.87 |
| 52-Week Range | 20.25 - 29.73 |
| Beta | 0.56 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 28, 2026 |
About Bausch + Lomb
Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lenses that are indicated for therapeutic use and provide optical correction during heali... [Read more]
Financial Performance
In 2025, Bausch + Lomb's revenue was $5.10 billion, an increase of 6.47% compared to the previous year's $4.79 billion. Losses were -$360.00 million, 13.6% more than in 2024.
Financial numbers in USD Financial StatementsNews
Bausch + Lomb price target raised to $20 from $16 at Deutsche Bank
Deutsche Bank analyst Pito Chickering raised the firm’s price target on Bausch + Lomb (BLCO) to $20 from $16 and keeps a Hold rating on the shares. Published first on…
Bausch + Lomb price target raised to $22 from $16 at JPMorgan
JPMorgan raised the firm’s price target on Bausch + Lomb (BLCO) to $22 from $16 and keeps a Neutral rating on the shares.
Bausch + Lomb announces publication of results from survey on dry eye symptoms
Bausch + Lomb (BLCO) announced the publication of results from a multinational survey examining symptoms, interactions with health care professionals and treatment experiences to better understand con...
Bausch + Lomb price target raised to $23 from $21 at Citi
Citi raised the firm’s price target on Bausch + Lomb (BLCO) to $23 from $21 and keeps a Buy rating on the shares.
Bausch + Lomb Announces Publication of Multinational Survey Results Highlighting the Burden of Dry Eye Symptoms and Opportunities for Improved Awareness and Patient Education
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the publicatio...
Bausch + Lomb Earnings Call Transcript: Q3 2026
Q3 revenue rose 8% on a constant-currency basis, while adjusted EBITDA increased 34% and free cash flow reached $178M. FY 2026 revenue and adjusted EBITDA guidance were raised, with net leverage down to 4.1x.
Bausch + Lomb Slides: Q3 2026
Bausch + Lomb has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on October 28, 2026.
Bausch + Lomb Earnings release: Q3 2026
Bausch + Lomb released its Q3 2026 earnings on October 28, 2026, summarizing the period's financial results.
Bausch + Lomb Quarterly report: Q3 2026
Bausch + Lomb has published its Q3 2026 quarterly earnings report on October 28, 2026.
Bausch + Lomb Swings to Profit and Lifts Outlook for Year
Bausch + Lomb increased its full-year outlook after logging a third-quarter profit, benefiting from rising revenue across its three segments.
Bausch + Lomb reports Q3 adjusted EPS 34c, consensus 22c
Reports Q3 revenue $1.375B, consensus $1.37B. “Our Q3 performance reflects the strength and breadth of the business, with growth across all three segments and continued expansion in profitability,” sa...
Bausch + Lomb raises FY26 revenue view to $5.450B-$5.550B from $5.440B-$5.540B
Consensus is for FY26 revenue $5.49B. Raises FY26 Full-Year Adjusted EBITDA view Excluding Acquired IPR&D $1.090B-$1.140B from $1.025B-$1.075B.
Bausch + Lomb Posts Strong Third-Quarter Performance, Raises Full-Year 2026 Guidance
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its third-quar...
Bausch + Lomb names Thomas Appio as interim CEO
Bausch + Lomb (BLCO) and its parent company, Bausch Health (BHC), announced that Bausch + Lomb Board of Directors Chairman Thomas Appio has been appointed interim chief executive officer, effective…
Bausch + Lomb, Bausch Health expect to raise FY26 adjusted EBITDA, ex IPR&D
Based on preliminary third-quarter results, Bausch + Lomb (BLCO) and Bausch Health (BHC) currently expect to raise full-year 2026 adjusted EBITDA excluding Acquired IPR&D guidance. The companies are c...
Bausch + Lomb and Bausch Health Announce Appointment of Thomas J. Appio as Interim Bausch + Lomb CEO, Expect to Raise Full-Year 2026 Guidance
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company, and its parent company, Bausch Health Companies Inc. (NYSE/TSX: BHC), today announce...
Bausch + Lomb advances oral treatment for dry AMD after FDA meeting
The company states: “Bausch + Lomb (BLCO) announced progress in the development of BL1243, tonabersat, an investigational oral treatment for dry age-related macular degeneration (AMD), following a con...
Bausch + Lomb Advances Novel Oral Treatment for Dry AMD Following Constructive FDA Meeting
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced progress in th...
Bausch + Lomb initiated with an Overweight at Barclays
Barclays analyst Christopher Pasquale initiated coverage of Bausch + Lomb (BLCO) with an Overweight rating and $24 price target The firm rolled out coverage of the medical suppliers and devices…
Bausch + Lomb Will Release Third-Quarter 2026 Financial Results on Oct. 28
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its third-quarter...
Bausch + Lomb announces European CE Mark approval of SeeLyra
Bausch + Lomb (BLCO) announced European CE Mark approval of SeeLyra, the company’s next generation femtosecond laser. One of the most compact femtosecond platforms available, SeeLyra provides surgeons...
Bausch + Lomb Announces European CE Mark Approval of SeeLyra™ Femtosecond Laser
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced European CE Ma...
Leerink bullish on Bausch + Lomb, initiates with an Outperform
As previously reported, Leerink initiated coverage of Bausch + Lomb (BLCO) with an Outperform rating and $24 price target The firm names the stock a Top Pick as current dry…
Bausch + Lomb initiated with an Outperform at Leerink
Leerink initiated coverage of Bausch + Lomb (BLCO) with an Outperform rating and $24 price target
Bausch + Lomb publishes new research on en Vista Aspire IOLs
Bausch + Lomb (BLCO) announced the publication of new research on real world experience with enVista Aspire and enVista Aspire toric intraocular lenses, or IOLs. The study, published in the…